Effect of sustained release terbutaline on symptoms and sleep quality in patients with nocturnal asthma.
Department of Respiratory Medicine, University of Edinburgh, City Hospital.
The effect of an oral sustained release beta 2 agonist on symptoms, sleep quality, and peak flow rates has been studied in nine patients with nocturnal asthma. Patients received oral terbutaline 7.5 mg twice daily or placebo for seven days in a double blind crossover study and spent the last two nights of each limb in a sleep laboratory. Oral terbutaline improved morning peak flow (259 v 213 l min-1) and decreased nocturnal inhaler usage (1.3 v 1.9) with no alteration in sleep quality as assessed electroencephalographically. The study shows that oral sustained release terbutaline can be useful in the treatment of nocturnal asthma without impairment of sleep quality.
This article has been cited by other articles:
-
WEERSINK, E. J. M., van ZOMEREN, E. H., KOETER, G. H., POSTMA, D. S.
(1997). Treatment of Nocturnal Airway Obstruction Improves Daytime Cognitive Performance in Asthmatics. Am. J. Respir. Crit. Care Med.
156: 1144-1150
[Abstract] [Full Text]
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
